Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo

Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo

Background/Aims: Mammalian target of rapamycin (mTOR) is a valuable treatment target of renal cell carcinoma (RCC). Palomid 529 is a novel mTORC1/2 dual inhibitor. Methods: RCC cells were treated with different concentrations of Palomid 529. Cell survival was tested by MTT assay and clonogenicity as...

Full description

Bibliographic Details
Main Authors: Zhao-yu Xing, Yin Wang, Long Cheng, Jie Chen, Xiao-zhou He, Wei  Xing
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-10-01
Series:Cellular Physiology and Biochemistry
Subjects:
Renal cell carcinoma
mTOR
Palomid 529
BRD4
Chemo-sensitization
Online Access:https://www.karger.com/Article/FullText/494185

Internet

https://www.karger.com/Article/FullText/494185

Similar Items